Antidote For THC? Anebulo Releases Positive Clinical Data Showing Potential Of Its Drug For Treatment Of Acute Cannabinoid Intoxication

Zinger Key Points
  • Delayed dosing of ANEB-001 rapidly reversed pre-existing THC effects.
  • ANEB-001 was well tolerated.

Anebulo Pharmaceuticals, Inc. ANEB announced complete results from its randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating ANEB-001 as a potential treatment for acute cannabinoid intoxication (ACI) in healthy volunteers challenged with oral THC. Part B of the study was an adaptive design that included six cohorts of up to 15 healthy adults to examine different doses of THC and ANEB-001, and the impact of delayed dosing of ANEB-001 or placebo. In total, Parts A and B of the phase 2 study enrolled 134 healthy subjects.

"The positive results of the Phase 2 proof of concept study are very encouraging and will have significant clinical implications for the unmet need of patients presenting to emergency departments with ACI," stated Simon Allen, CEO of Anebulo. "We believe the complete data from this study, together with data from our observational study in ACI subjects and our PK/PD modeling efforts, will provide support for the design of a registrational trial. We are in the process of requesting an end of phase 2A meeting with FDA to discuss the final data from this study. We expect the meeting to occur within 75 days from the date of the request but acknowledge that it could be longer."

Final ANEB-001 Part 2 Proof of Concept Study Results

Based on the final data for part B of the study, a single low oral dose of ANEB-001 (10 mg) administered 1 hour after a THC challenge rapidly and statistically significantly reversed key psychotropic effects of THC doses as high as 30 mg, including a reduction in the visual analog scale (VAS) for feeling high and improvement in VAS alertness and reduced body sway. In a pre-specified pooled analysis of data for the combined 21 mg or 30 mg THC dose levels, a single 10 mg of ANEB-001 administered one hour after THC achieved statistical significance on all primary outcomes, including a reduction in VAS feeling high, improvement in VAS alertness, reduced body sway, and reduction in heart rate. ANEB-001 also reduced the time required for the THC effects to normalize back to baseline.

Benzinga's Cannabis Capital Conference Is Back

The most successful cannabis business event in the world, the Benzinga Cannabis Capital Conference, returns to Miami for its 16th edition. This is the place where DEALS GET DONE, where money is raised, M&A starts, and companies meet investors and key partners. Join us at the Fontainebleau Miami Beach Hotel in Florida on April 11-12. Don’t miss out. Secure your tickets now. Prices will surge very soon.

Photo by Louis Reed on Unsplash

Market News and Data brought to you by Benzinga APIs
Posted In: CannabisNewsPenny StocksMarketspremiumSimon Allen
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Benzinga Cannabis Capital Conference is coming to Florida

The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.

Get your tickets now on – Prices will increase very soon!